Nasdaq

NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy

SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ...
Business Wire

NanoString Platforms Advance Groundbreaking Studies of Immune Response in Pig-to-Human Organ Transplants

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced today that a team of globally ...
Business Wire

NanoString Technologies Releases Operating Results for Second Quarter of 2023

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the ...
FierceBiotech

NanoString touts positive data after middling IPO

NanoString's Prosigna tests works with its nCounter analyzer.--Courtesy of NanoString NanoString ($NSTG) is working to expand the adoption of its breast cancer ...
Business Insider

NanoString Announces Launch of Breast Cancer 360 Research Panel, Expanding the 360 Series of Cancer Panels for Translational Research and Signature Development

SEATTLE, April 10, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced ...
FierceBiotech

NanoString to produce companion test for Celgene's blockbuster cancer drug Revlimid

Seattle's NanoString Technologies ($NSTG) stands to make up to $45 million if it can come up with a successful companion diagnostic test to screen for a subset of ...